Initial research are sparking significant interest surrounding Novo Nordisk's new drug , a innovative dual treatment targeting gut peptides and glucose-dependent insulinotropic polypeptide. Unlike existing weight loss therapies , the drug shows to deliver substantial decreases in body fat and enhance insulin health in clinical assessments . While